ATE345504T1 - Screeningverfahren für peptide, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteine inhibieren - Google Patents

Screeningverfahren für peptide, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteine inhibieren

Info

Publication number
ATE345504T1
ATE345504T1 AT02291170T AT02291170T ATE345504T1 AT E345504 T1 ATE345504 T1 AT E345504T1 AT 02291170 T AT02291170 T AT 02291170T AT 02291170 T AT02291170 T AT 02291170T AT E345504 T1 ATE345504 T1 AT E345504T1
Authority
AT
Austria
Prior art keywords
bcl
proteins
binding
pp1c
screening methods
Prior art date
Application number
AT02291170T
Other languages
English (en)
Inventor
Alphonse Garcia
Xavier Cayla
Angelita Rebollo
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE345504T1 publication Critical patent/ATE345504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
AT02291170T 2002-05-07 2002-05-07 Screeningverfahren für peptide, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteine inhibieren ATE345504T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02291170A EP1361439B1 (de) 2002-05-07 2002-05-07 Screeningverfahren für Peptide, die die Bindung von PP1c an Bcl-2, BCL-Xl und BCL-W Proteine inhibieren

Publications (1)

Publication Number Publication Date
ATE345504T1 true ATE345504T1 (de) 2006-12-15

Family

ID=29225746

Family Applications (4)

Application Number Title Priority Date Filing Date
AT02291170T ATE345504T1 (de) 2002-05-07 2002-05-07 Screeningverfahren für peptide, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteine inhibieren
AT06023212T ATE434186T1 (de) 2002-05-07 2002-05-07 Screeningverfahren für pp1-wechselwirkende polypeptide oder proteine, peptide, die die bindung von pp1c an die proteine bcl-2, bcl-xl und bcl-w hemmen, und ihre verwendung
AT03749894T ATE382864T1 (de) 2002-05-07 2003-05-06 Screeningverfahren für peptiden, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteinen inhibieren
AT07025179T ATE472104T1 (de) 2002-05-07 2003-05-06 Screeningverfahren für peptide, die die bindung von pp1c an die proteine bcl-2, bcl-xl und bcl-w hemmen

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT06023212T ATE434186T1 (de) 2002-05-07 2002-05-07 Screeningverfahren für pp1-wechselwirkende polypeptide oder proteine, peptide, die die bindung von pp1c an die proteine bcl-2, bcl-xl und bcl-w hemmen, und ihre verwendung
AT03749894T ATE382864T1 (de) 2002-05-07 2003-05-06 Screeningverfahren für peptiden, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteinen inhibieren
AT07025179T ATE472104T1 (de) 2002-05-07 2003-05-06 Screeningverfahren für peptide, die die bindung von pp1c an die proteine bcl-2, bcl-xl und bcl-w hemmen

Country Status (12)

Country Link
US (2) US7741288B2 (de)
EP (4) EP1788394B1 (de)
AT (4) ATE345504T1 (de)
AU (1) AU2003242569A1 (de)
CA (1) CA2484211A1 (de)
CY (2) CY1107367T1 (de)
DE (4) DE60232691D1 (de)
DK (3) DK1788394T3 (de)
ES (3) ES2327773T3 (de)
PT (3) PT1788394E (de)
SI (1) SI1502116T1 (de)
WO (1) WO2003096022A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
US8455628B2 (en) * 2007-05-02 2013-06-04 Intrexon Corporation PP1 ligands
EP2348038A1 (de) * 2010-01-22 2011-07-27 Philipps-Universität Marburg Verfahren zur Bestimmung der Aktivität der Transglutaminase Faktor XIIIa
CN106456699B (zh) * 2014-05-05 2021-07-02 生物风险投资有限责任公司 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
US20170056422A1 (en) * 2014-05-07 2017-03-02 Seattle Biomedical Research Institute Plasmodium liver-stage inhibitors and related methods
CA2955972A1 (en) 2014-07-22 2016-01-28 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN108218962B (zh) * 2017-12-29 2021-06-08 广西中医药大学 小分子多肽及其用途
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
WO2019221755A1 (en) 2018-05-18 2019-11-21 Bioventures, Llc Piperlongumine analogues and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
WO1997037224A1 (en) * 1996-03-30 1997-10-09 Medical Research Council Protein phosphatase-1 catalytic subunit interactions
JP4544715B2 (ja) * 1999-08-17 2010-09-15 成男 太田 ラットｂｃｌ−ｘ遺伝子の改変型ｃＤＮＡと改変型タンパク質
US7521548B2 (en) * 2001-02-07 2009-04-21 Burnham Institute For Medical Research Apoptosis modulator Bcl-B and methods for making and using same
WO2002074931A2 (en) * 2001-03-20 2002-09-26 University Of Chicago Inhibitors and disassemblers of fibrillogenesis
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
EP1502116A2 (de) 2005-02-02
DK1788394T3 (da) 2009-10-19
AU2003242569A8 (en) 2003-11-11
DE60232691D1 (de) 2009-07-30
PT1502116E (pt) 2008-04-15
EP1933150A1 (de) 2008-06-18
US20110028387A1 (en) 2011-02-03
EP1788394A1 (de) 2007-05-23
ES2327773T3 (es) 2009-11-03
ATE434186T1 (de) 2009-07-15
DE60216048D1 (de) 2006-12-28
WO2003096022A3 (en) 2004-04-01
DE60216048T2 (de) 2007-05-31
ATE382864T1 (de) 2008-01-15
CY1109383T1 (el) 2014-07-02
HK1119249A1 (en) 2009-02-27
EP1361439A1 (de) 2003-11-12
PT1788394E (pt) 2009-08-13
PT1361439E (pt) 2007-02-28
WO2003096022A8 (en) 2004-06-03
CA2484211A1 (en) 2003-11-20
DK1361439T3 (da) 2007-03-26
EP1788394B1 (de) 2009-06-17
US7741288B2 (en) 2010-06-22
US20050244844A1 (en) 2005-11-03
EP1933150B1 (de) 2010-06-23
HK1078337A1 (en) 2006-03-10
EP1502116B1 (de) 2008-01-02
SI1502116T1 (sl) 2008-06-30
WO2003096022A2 (en) 2003-11-20
AU2003242569A1 (en) 2003-11-11
ES2300603T3 (es) 2008-06-16
ES2276895T3 (es) 2007-07-01
DE60318427D1 (de) 2008-02-14
ATE472104T1 (de) 2010-07-15
DE60333138D1 (de) 2010-08-05
HK1062198A1 (en) 2004-10-21
CY1107367T1 (el) 2012-12-19
DK1502116T3 (da) 2008-05-13
EP1361439B1 (de) 2006-11-15
DE60318427T2 (de) 2008-12-18

Similar Documents

Publication Publication Date Title
CY1109383T1 (el) Σαρωση για πεπτιδια που αναστελλουν την προσδεση της pp1c, στις πρωτεϊνες bcl-2, bcl-xl και bcl-w
Backes et al. An alkanesulfonamide “safety-catch” linker for solid-phase synthesis
DK1521774T3 (da) Trunkerede Tau-proteiner
NO962991L (no) Zink-finger-proteinderivater og fremgangsmåter derav
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
BRPI0616712B8 (pt) método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
ATE506370T1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
ATE439856T1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
DK1387854T3 (da) SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf
EP1666880A4 (de) Screening-verfahren
WO2003060067A3 (en) P85-alpha nucleic acids, polypeptides and related methods
ATE485831T1 (de) Behandlung von neurodegeneration
WO2005014638A3 (fr) Peptide interagissant avec les proteines anti-apoptotiques de la famille bcl-2
EP3771719A8 (de) An tau-protein bindendes peptid
CA2530731A1 (en) Peptide having apoptosis-inhibiting activity
DE69812597D1 (de) Peptide zur Inhibition von HPV E7 Proteinen
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
WO2002074804A3 (en) Use of binding domains of presenilins and transmembrane proteins for drug screening
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
EP1455186A4 (de) Screening-verfahren
DK2186898T3 (da) Blomstrings-induktion
ATE375995T1 (de) Verfahren zur synthese von peptiden, die mindestens ein glycinmolekül enthalten
ATE465175T1 (de) Neuer proteinkomplex und anwendungen davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1361439

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee